newsfilter
← Latest News
GlobeNewswire·

AVEO Oncology Reports Third Quarter 2022 Financial Results

– Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Announced entering a definitive agreement under which LG Chem will acquire AVEO for $15.00